ERA 2023 – longer is stronger for Vera
Proteinuria data with Vera’s IgAN project atacicept have improved over time, with a surprise benefit on the hard eGFR endpoint.
EHA 2023 – Astrazeneca keeps up its complement defence
With Novartis’s oral contender looming, Astra talks up the importance of terminal complement inhibition.
Asco 2023 movers – maintaining the momentum
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
Asco 2023 – Novocure sinks as Lunar’s limitations become clear
A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.